Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates and FY 2013 Operating Profit Guidance Above Analysts' Estimates; Proposes FY 2012 Dividend


Thursday, 31 Jan 2013 01:29am EST 

Novo Nordisk A/S announced that for the fiscal year 2013, sales (revenue) growth measured in local currencies is expected to be between 8% and 11%, and operating profit growth measured in local currencies is expected to be around 10%. For the fiscal year 2012, the Company reported revenue of DKK 78,026 million and operating profit of DKK 29,474 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of DKK 85,681.20 million and operating profit of DKK 30,067 million for the fiscal year 2013. In addition, the Company announced that at the Annual General Meeting on March 20, 2013, the Board of Directors will propose a 29% increase in dividend to DKK 18 per share. 

Company Quote

47.69
-0.62 -1.28%
4:01pm EDT